Splenectomy in patients with myeloproliferative neoplasms: Efficacy, complications and impact on survival and transformation

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 121-127

  Santos, Fabio P S ^a   Tam, Constantine S ^b   Kantarjian, Hagop ^c   Cortes, Jorge ^c   Thomas, Deborah ^c   Pollock, Raphael ^c   Verstovsek, Srdan ^c  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; Myelofibrosis; Myeloproliferative neoplasms; Splenectomy; Survival

Indexed keywords

ALKYLATING AGENT; HYDROXYUREA; INTERFERON; PROTEIN TYROSINE KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE COURSE; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SPLEEN; SPLENECTOMY; SURGICAL MORTALITY; THROMBOCYTOPENIA; THROMBOCYTOSIS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; PRIMARY MYELOFIBROSIS; PROGNOSIS; SPLENECTOMY; SPLENOMEGALY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891360270     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.794269     Document Type: Article

References (38)

1. Visani G, Finelli C, Castelli U, et al. Myelofi brosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients. Br J. Haematol 1990; 75: 4-9.
2. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofi brosis based on a study of the International Working Group for Myelofi brosis Research and Treatment. Blood 2009; 113: 2895-2901.
3. Mesa RA, Schwager S, Radia D, et al. The Myelofi brosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofi brosis. Leuk Res 2009; 33: 1199-1203.
4. Abu-Hilal M, Tawaker J. Portal hypertension secondary to myelofi brosis with myeloid metaplasia: A study of 13 cases. World J. Gastroenterol 2009; 15: 3128-3133.
5. Mesa RA, Elliott MA, Tefferi A. Splenectomy in chronic myeloid leukemia and myelofi brosis with myeloid metaplasia. Blood Rev 2000; 14: 121-129.
6. Mesa RA, Tefferi A. P alliative splenectomy in myelofi brosis with myeloid metaplasia. Leuk Lymphoma 2001; 42: 901-911.
7. Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofi brosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361-370.
8. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofi brosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000; 95: 2226-2233.
9. Akpek G, McAneny D, Weintraub L. Risks and benefi ts of splenectomy in myelofi brosis with myeloid metaplasia: A retrospective analysis of 26 cases. J. Surg Oncol 2001; 77: 42-48.
10. Benbassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J. Hematol 1990; 33: 128-135.
11. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebocontrolled trial of ruxolitinib for myelofi brosis. N Engl J. Med 2012; 366: 799-807.
12. Harrison C, Kiladjian JJ, A l-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofi brosis. N Engl J. Med 2012; 366: 787-798.
13. Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofi brosis. In Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC Press; 2008. pp 44-47.
14. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofi brosis with myeloid metaplasia, for the IWG for Myelofi brosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497-1503.
15. Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009. An International System for Human Cytogenetic Nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland: Karge r; 2009.
16. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus. a refi ned Dynamic International Prognostic Scoring System for primary myelofi brosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin Oncol 2011; 29: 392-397.
17. Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofi brosis. applicability at the time of diagnosis and later during disease course. Blood 2009; 113: 4171-4178.
18. Passamonti F, Cervantes F, Vannucchi A M,et al. A dynamic prognostic model to predict survival in primary myelofi brosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
19. Snedecor G, Cochran W. Statistical methods. 7th ed. Armes, IA: Iowa State University Pres s; 1980.
20. Schemper M, Smith T L. Anote on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
21. Cox D. R egression models and life tables. J. R Stat Soc 1 972; 3 4: 187-202.
22. Mantel N, Byar D. E valuation of response-Time data involving transient states. An illustration using heart-Transplant data. J. Am Stat Assoc 1974; 69: 81-86.
23. Jabbour E, Th omas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofi brosis. Blood 2011; 118: 899-902.
24. Thapaliya P, Tefferi A, Pardanani A, et al. International working group for myelofi brosis research and treatment response assessment and long-Term follow-up of 50 myelofi brosis patients treated with thalidomide-prednisone based regimens. Am J. Hematol 2011; 86: 96-98.
25. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofi brosis. J. Clin Oncol 2009; 27: 4563-4569.
26. Ghanima W, Junker P, Hasselbalch HC, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J. Haematol 2011; 155: 248-255.
27. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or postpolycythemia vera/essential thrombocythemia myelofi brosis. J. Clin Oncol 2009; 27: 5587-5593.
28. Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofi brosis. a study of 172 patients. Blood 2010; 115: 4350-4355.
29. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofi brosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998; 91: 3630-3636.
30. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofi brosis. Cancer 2008; 112: 2726-2732.
31. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J. Med 1993; 329: 1152-1157.
32. Tura S, Fiacchini M, Zinzani PL, et al. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. J. Clin Oncol 1993; 11: 925-930.
33. Dietrich PY, Henry-Amar M, Cosset JM, et al. Second primary cancers in patients continuously disease-free from Hodgkin's disease: A protective role for the spleen? Blood 1994; 84: 1209-1215.
34. Lopez-Guillermo A, Cervantes F, Bruguera M, et al. Liver dysfunction following splenectomy in idiopathic myelofi brosis: A study of 10 patients. Acta Haematol 1991; 85: 184-188.
35. Jais X, Ioos V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Th orax 2005; 60: 1031-1034.
36. Porcu P, Neiman RS, Orazi A. Splenectomy in agnogenic myeloid metaplasia. Blood 1999; 93: 2132-2134.
37. O ' B rien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J. Med 2003; 348: 994-1004.
38. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34 (-) cells in myelofi brosis with myeloid metaplasia. Blood 2001; 98: 3249-3255.